Drug Search Results
More Filters [+]

Netazepide

Alternative Names: netazepide, yf476
Latest Update: 2024-04-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: CCK Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Trio Medicines
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Netazepide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Barrett Esophagus|Carcinoid Tumor|Gastrinoma|Gastritis, Atrophic|Gastritis|Zollinger-Ellison Syndrome|Healthy Volunteers

Phase 1: Healthy Volunteers|Esophagitis, Peptic|Dyspepsia|Pregnancy Outcomes|Peptic Ulcer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

YF476 and type I gastric carcinoids

P2

Completed

Gastritis, Atrophic

2020-01-27

Netazepide (YF476) in patients with Barrett's oesophagus; version 1

P2

Completed

Barrett Esophagus

2019-10-10

AAAE9648

P2

Completed

Barrett Esophagus

2017-12-01

T-016

P2

Completed

Barrett Esophagus

2017-11-28

Recent News Events